Monitor for actual sales activity under this ATM program, as continuous equity issuance could pressure the stock price, especially given the company's $95M market cap. The lack of disclosed use of proceeds increases uncertainty around capital efficiency.
Price Chart
Executive Summary
Q32 Bio Inc. has filed an additional prospectus supplement to raise up to $75 million through its at-the-market (ATM) offering program with Cantor Fitzgerald, following the full utilization of a prior $14.2 million ATM offering. This new shelf capacity provides continued access to equity funding for the clinical-stage biotech.
Key Facts
- Q32 Bio has fully drawn down a prior $14.2 million ATM offering with Cantor Fitzgerald
- Filed a new prospectus supplement to offer up to $75 million in common stock via the same ATM program
- The offering is under a shelf registration (Form S-3) declared effective April 21, 2025
- No specific use of proceeds or pricing details disclosed in this filing
Financial Impact
$75 million in potential equity dilution
Risk Factors
- Significant shareholder dilution from potential $75M in new share issuance
- Downward pressure on stock price due to overhang from ATM program
- Lack of transparency on use of proceeds raises capital allocation concerns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-177178 |
| Document: d31430dex51.htm | 0001193125-26-177178 |
| Document: 0001193125-26-177178-index-headers.html | 0001193125-26-177178 |
| Document: 0001193125-26-177178-index.html | 0001193125-26-177178 |
| Document: 0001193125-26-177178.txt | 0001193125-26-177178 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $10.91 $10.47 | ▼ −4.03% | ▼ −4.14% | $8.23 (−24.56%) |
Aug 27, 2026 5w ago | Insider Cluster | $16.15 $12.80 | ▼ −20.74% | ▼ −21.01% | $8.23 (−49.04%) |
Aug 5, 2026 8w ago | 8-K | $16.49 $15.37 | ▼ −6.79% | ▼ −7.14% | $8.23 (−50.09%) |
Jul 15, 2026 11w ago | Press Release | $15.70 $15.08 | ▲ +3.95% | ▲ +2.97% | $8.23 (+47.58%) |
Jul 14, 2026 11w ago | EFFECT | $18.46 $15.04 | ▼ −18.53% | ▼ −17.23% | $8.23 (−55.42%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jun 25, 2026 14w ago | S-3 | $13.17 $13.09 | ▼ −0.61% | ▼ −2.77% | $8.23 (−37.51%) |
Jun 2, 2026 17w ago | Insider Cluster | $12.64 $11.89 | ▼ −5.93% | ▼ −2.97% | $8.23 (−34.89%) |
May 5, 2026 21w ago | 8-K | $5.14 $5.81 | ▲ +13.04% | ▲ +11.05% | $8.23 (+60.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access